Research programme: Immunostimulant antibody conjugates - Bolt Biotherapeutics/Toray Industries
Latest Information Update: 30 May 2024
At a glance
- Originator Bolt Biotherapeutics; Toray Industries
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 10 May 2023 Bolt Biotherapeutics terminates its license with Stanford University for Boltbody™ platform (SEC File 2023- Bolt Biotherapeutics)
- 17 Jan 2023 Early research in Cancer in China (Parenteral) (Bolt Biotherapeutics pipeline, January 2023)
- 08 Jun 2020 Bolt Biotherapeutics has patent protection for Boltbody™ ISAC technology platform in USA